Current Pharmaceutical Design, Volume 19 - Number 5


Editorial (Hot Topic: Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer)

, 19(5): 807

E. Giovannetti and G.J. Peters

DOI: 10.2174/1381612811306050807

Targeting HER Receptors in Cancer

, 19(5): 808 - 817

Alberto Ocana and Atanasio Pandiella

DOI: 10.2174/1381612811306050808

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer

, 19(5): 818 - 832

Elena Galvani, Roberta Alfieri, Elisa Giovannetti, Andrea Cavazzoni, Silvia La Monica, Maricla Galetti, Claudia Fumarola, Mara Bonelli, Marco Mor, Marcello Tiseo, Godefridus J. Peters, Pier Giorgio Petronini and Andrea Ardizzoni

DOI: 10.2174/1381612811306050818

Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors

, 19(5): 833 - 840

J. Voortman, T. Harada, R.P. Chang, J.K. Killian, M. Suuriniemi, W.I. Smith, P.S. Meltzer, M. Lucchi, Y. Wang and G. Giaccone

DOI: 10.2174/1381612811306050833

Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways

, 19(5): 841 - 863

Clara Lemos, Ulrike Sack, Felicitas Schmid, Manisha Juneja and Ulrike Stein

DOI: 10.2174/1381612811306050841

Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers

, 19(5): 864 - 882

Libero Santarpia and Giulia Bottai

DOI: 10.2174/1381612811306050864

Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway

, 19(5): 883 - 894

Giacomo Cossa, Laura Gatti, Giuliana Cassinelli, Cinzia Lanzi, Nadia Zaffaroni and Paola Perego

DOI: 10.2174/1381612811306050883

PI3K Pathway Inhibitors: Better Not Left Alone

, 19(5): 895 - 906

Ben Markman, Jessica J. Tao and Maurizio Scaltriti

DOI: 10.2174/1381612811306050895

The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors

, 19(5): 907 - 917

An Wouters, Carolien Boeckx, Jan B. Vermorken, Danielle Van den Weyngaert, Marc Peeters and Filip Lardon

DOI: 10.2174/1381612811306050907

Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors

, 19(5): 918 - 926

L. Porcelli, A.E. Quatrale, P. Mantuano, N. Silvestris, J.F. Rolland, L. Biancolillo, A. Paradiso and A. Azzariti

DOI: 10.2174/1381612811306050918

Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells

, 19(5): 927 - 939

E. Giovannetti, M. Labots, H. Dekker, E. Galvani, J.S.W. Lind, R. Sciarrillo, R. Honeywell, E.F. Smit, H.M. Verheul and G.J. Peters

DOI: 10.2174/1381612811306050927

Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer

, 19(5): 940 - 950

Amir Avan, Karl Quint, Francesco Nicolini, Niccola Funel, Adam E. Frampton, Mina Maftouh, Serena Pelliccioni, Gerrit J. Schuurhuis, Godefridus J. Peters and Elisa Giovannetti

DOI: 10.2174/1381612811306050940

Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma

, 19(5): 951 - 957

Ravi S. Narayan, Carlos Alexandre Fedrigo, Lukas J.A. Stalpers, Brigitta G. Baumert and Peter Sminia

DOI: 10.2174/1381612811306050951

Irinotecan Resistance is Accompanied by Upregulation of EGFR and Src Signaling in Human Cancer Models

, 19(5): 958 - 964

Amelie Petitprez and Annette K. Larsen

DOI: 10.2174/1381612811306050958

Webmaster Contact:
Copyright © 2018 Bentham Science